562 related articles for article (PubMed ID: 26943322)
1. Onto better TRAILs for cancer treatment.
de Miguel D; Lemke J; Anel A; Walczak H; Martinez-Lostao L
Cell Death Differ; 2016 May; 23(5):733-47. PubMed ID: 26943322
[TBL] [Abstract][Full Text] [Related]
2. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
Martinez-Lostao L; Marzo I; Anel A; Naval J
Biochem Pharmacol; 2012 Jun; 83(11):1475-83. PubMed ID: 22230480
[TBL] [Abstract][Full Text] [Related]
4. TRAIL death receptors and cancer therapeutics.
Huang Y; Sheikh MS
Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
[TBL] [Abstract][Full Text] [Related]
5. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
6. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
7. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.
Falschlehner C; Ganten TM; Koschny R; Schaefer U; Walczak H
Adv Exp Med Biol; 2009; 647():195-206. PubMed ID: 19760076
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of TRAIL receptor agonists in cancer treatment.
Fulda S
Eur J Clin Pharmacol; 2015 May; 71(5):525-7. PubMed ID: 25704217
[TBL] [Abstract][Full Text] [Related]
9. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Tuthill MH; Montinaro A; Zinngrebe J; Prieske K; Draber P; Prieske S; Newsom-Davis T; von Karstedt S; Graves J; Walczak H
Oncogene; 2015 Apr; 34(16):2138-2144. PubMed ID: 24909167
[TBL] [Abstract][Full Text] [Related]
10. Developing TRAIL/TRAIL death receptor-based cancer therapies.
Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
[TBL] [Abstract][Full Text] [Related]
11. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W
Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
Singh D; Tewari M; Singh S; Narayan G
Future Oncol; 2021 Feb; 17(5):581-596. PubMed ID: 33401962
[TBL] [Abstract][Full Text] [Related]
14. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
15. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
16. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.
Bellail AC; Qi L; Mulligan P; Chhabra V; Hao C
Rev Recent Clin Trials; 2009 Jan; 4(1):34-41. PubMed ID: 19149761
[TBL] [Abstract][Full Text] [Related]
17. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
18. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
[TBL] [Abstract][Full Text] [Related]
19. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
Dai X; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
Exp Biol Med (Maywood); 2015 Jun; 240(6):760-73. PubMed ID: 25854879
[TBL] [Abstract][Full Text] [Related]
20. The TRAIL to cancer therapy: Hindrances and potential solutions.
Wong SHM; Kong WY; Fang CM; Loh HS; Chuah LH; Abdullah S; Ngai SC
Crit Rev Oncol Hematol; 2019 Nov; 143():81-94. PubMed ID: 31561055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
